Clover Health Investments Statistics
Total Valuation
CLOV has a market cap or net worth of $1.13 billion. The enterprise value is $940.14 million.
Important Dates
The last earnings date was Tuesday, August 5, 2025, after market close.
| Earnings Date | Aug 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CLOV has 510.76 million shares outstanding. The number of shares has increased by 3.01% in one year.
| Current Share Class | 418.39M |
| Shares Outstanding | 510.76M |
| Shares Change (YoY) | +3.01% |
| Shares Change (QoQ) | +2.41% |
| Owned by Insiders (%) | 21.53% |
| Owned by Institutions (%) | 26.00% |
| Float | 398.93M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.69 |
| Forward PS | 0.55 |
| PB Ratio | 3.28 |
| P/TBV Ratio | 3.31 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.58 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.80
| Current Ratio | 1.80 |
| Quick Ratio | 1.65 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -12.59% and return on invested capital (ROIC) is -7.91%.
| Return on Equity (ROE) | -12.59% |
| Return on Assets (ROA) | -4.26% |
| Return on Invested Capital (ROIC) | -7.91% |
| Return on Capital Employed (ROCE) | -11.42% |
| Revenue Per Employee | $2.82M |
| Profits Per Employee | -$75,612 |
| Employee Count | 570 |
| Asset Turnover | 2.57 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +20.77% in the last 52 weeks. The beta is 1.92, so CLOV's price volatility has been higher than the market average.
| Beta (5Y) | 1.92 |
| 52-Week Price Change | +20.77% |
| 50-Day Moving Average | 2.93 |
| 200-Day Moving Average | 3.51 |
| Relative Strength Index (RSI) | 28.71 |
| Average Volume (20 Days) | 9,968,770 |
Short Selling Information
The latest short interest is 36.20 million, so 7.09% of the outstanding shares have been sold short.
| Short Interest | 36.20M |
| Short Previous Month | 42.08M |
| Short % of Shares Out | 7.09% |
| Short % of Float | 9.07% |
| Short Ratio (days to cover) | 2.92 |
Income Statement
In the last 12 months, CLOV had revenue of $1.61 billion and -$43.10 million in losses. Loss per share was -$0.09.
| Revenue | 1.61B |
| Gross Profit | 383.65M |
| Operating Income | -42.60M |
| Pretax Income | -123.70M |
| Net Income | -43.10M |
| EBITDA | -41.06M |
| EBIT | -42.60M |
| Loss Per Share | -$0.09 |
Full Income StatementBalance Sheet
The company has $201.27 million in cash and n/a in debt, giving a net cash position of $188.65 million or $0.37 per share.
| Cash & Cash Equivalents | 201.27M |
| Total Debt | n/a |
| Net Cash | 188.65M |
| Net Cash Per Share | $0.37 |
| Equity (Book Value) | 344.18M |
| Book Value Per Share | 0.67 |
| Working Capital | 160.99M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$46.73 million and capital expenditures -$1.47 million, giving a free cash flow of -$48.20 million.
| Operating Cash Flow | -46.73M |
| Capital Expenditures | -1.47M |
| Free Cash Flow | -48.20M |
| FCF Per Share | -$0.09 |
Full Cash Flow StatementMargins
Gross margin is 23.86%, with operating and profit margins of -2.65% and -2.68%.
| Gross Margin | 23.86% |
| Operating Margin | -2.65% |
| Pretax Margin | -2.62% |
| Profit Margin | -2.68% |
| EBITDA Margin | -2.55% |
| EBIT Margin | -2.65% |
| FCF Margin | n/a |
Dividends & Yields
CLOV does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.01% |
| Shareholder Yield | -3.01% |
| Earnings Yield | -3.82% |
| FCF Yield | -4.27% |
Dividend DetailsAnalyst Forecast
The average price target for CLOV is $4.37, which is 97.74% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $4.37 |
| Price Target Difference | 97.74% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 17.79% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
